A blood pressure reading and a question

A participant sits in the clinic chair, cuff deflating. The reading appears: 158/96 mmHg. At the prior visit, two weeks ago, it was 132/84. The participant feels fine -- no headache, no blurred vision, no chest discomfort. Just a number on a screen.

Is this an adverse event?

The honest answer -- the answer that separates competent coordinators from truly skilled ones -- is: it depends. And what it depends on is the subject of this entire lesson. It depends on what the protocol defines as a reportable vital sign threshold. It depends on whether the investigator considers this change clinically significant. It depends on context that no automated system can evaluate -- did the participant rush into the clinic from the parking garage? Did they forget their antihypertensive medication this morning? Have prior readings shown an upward trend, or is this an isolated spike?

In the previous lesson, you learned how to elicit adverse events through what participants tell you -- their subjective reports. This lesson shifts to what the data tells you. Vital sign measurements, physical examination findings, and clinical observations are objective indicators that can reveal adverse events the participant does not feel, does not notice, or does not think to mention. But unlike a participant who says "I have been having terrible headaches," an elevated blood pressure reading does not announce itself as an adverse event. It requires interpretation. And interpretation requires a framework.

From measurement to determination: the vital sign pathway

Every vital sign collected during a study visit follows a decision pathway, whether the coordinator recognizes it or not. Making that pathway explicit -- and following it deliberately -- is what ensures consistent, defensible AE identification.

The pathway has four steps:

Step 1 -- Value obtained. The coordinator measures the vital sign according to the protocol's specifications: correct technique, correct timing, correct conditions. (This course assumes you know how to measure vital signs accurately. What we teach here is what to do with the number once you have it.)

Step 2 -- Compare against protocol thresholds. The coordinator checks the value against whatever thresholds the protocol defines. Does this reading exceed an absolute threshold? Does the change from baseline exceed a protocol-defined limit? This is a factual comparison, not a judgment call.

Step 3 -- Investigator assesses clinical significance. If the value meets or exceeds a threshold, or if the coordinator identifies a change that warrants medical review, the investigator evaluates whether the finding is clinically significant. This is the step where medical judgment enters the process.

Step 4 -- Determination. If the investigator determines the finding is clinically significant, it is documented as an adverse event. If not, the value is still recorded in the source documents -- it is part of the clinical record -- but no AE entry is generated.

This is the pathway for all objective findings. It applies to blood pressure, heart rate, temperature, respiratory rate, oxygen saturation, weight, and physical examination observations. The specifics change with each vital sign, but the decision architecture remains the same.

Protocol thresholds: absolute versus change-from-baseline

Not all protocols define vital sign thresholds the same way. I have reviewed protocols from dozens of sponsors, and the variation is considerable. Understanding which approach your protocol uses is not optional preparation -- it is essential knowledge that must be mastered before the first participant visit.

Absolute thresholds define a fixed value that triggers assessment. For example: "A systolic blood pressure greater than 180 mmHg or less than 90 mmHg requires AE evaluation." The advantage of absolute thresholds is simplicity -- anyone can compare a measured value against a fixed number. The limitation is that they ignore the participant's starting point. A participant whose baseline systolic pressure is 170 mmHg is a different clinical situation than a participant whose baseline is 110 mmHg, even when both read 185 mmHg at a study visit.

Change-from-baseline thresholds define a reportable change relative to the participant's own baseline. For example: "A heart rate increase of greater than 25% from baseline requires AE evaluation." These thresholds are more sensitive to individual variation -- they detect meaningful change even when the absolute value remains within normal limits. A heart rate increase from 72 bpm to 92 bpm does not breach any absolute threshold, but it represents a 28% increase that would trigger assessment under a 25% change-from-baseline rule.

Combined approaches use both. A protocol might require AE evaluation for "systolic blood pressure greater than 180 mmHg OR an increase greater than 30 mmHg from baseline." This captures both the participant who reaches a dangerous absolute level and the participant who experiences a large shift from their personal normal.

The examples in the table above are illustrative -- your protocol may use entirely different values, and some protocols leave vital sign AE thresholds to investigator discretion without specifying numerical cutoffs at all. The point is not to memorize these numbers. The point is to know where your protocol defines its thresholds, what type of threshold it uses, and how to apply it at every visit.

A practical recommendation: before the first participant visit on any study, create a reference card -- a single page that lists every vital sign threshold the protocol defines, the type of threshold (absolute, change-from-baseline, or combined), and the required action when a threshold is breached. Keep this card at the vital signs station. When a reading appears abnormal, you should not need to flip through a 300-page protocol to determine whether it exceeds the threshold. That information should be immediately accessible.

Clinical significance: the gateway concept

This is, in my view, the most important concept in this lesson -- and one of the most important in the entire course. If you understand clinical significance and how it operates as a gateway between abnormal findings and adverse events, you will navigate the gray areas of objective AE identification with confidence. If you do not, you will either over-report (flagging every out-of-range value as an AE) or under-report (dismissing meaningful changes because the participant "feels fine").

Here is the principle, stated plainly:

An abnormal value is not automatically an adverse event. It becomes an adverse event when the investigator determines it is clinically significant.

This applies to vital signs, laboratory values (which the next lesson covers in detail), and physical examination findings. The normal range for a given parameter is a statistical construct -- it defines the central 95% of values in a healthy reference population. By definition, 5% of healthy individuals fall outside the normal range at any given time without any pathology. A blood pressure of 142/88 mmHg may be outside the textbook normal range, but if the participant has a documented history of controlled hypertension and this reading is consistent with their usual values, it is not a clinically significant finding in the context of this study.

Presenting data to support investigator judgment

The investigator's clinical significance determination is only as good as the information the coordinator puts in front of them. Telling the investigator "the blood pressure was high" is not the same as presenting a complete clinical picture. And the difference matters -- not in theory, but at the moment when the investigator must decide whether to document a finding as an adverse event.

When bringing a vital sign concern to the investigator, the coordinator should present:

The current value and the context. Not just "158/96" but "158/96, measured after five minutes of seated rest per protocol specifications."

Prior values. What were the participant's readings at baseline and at previous visits? Is this value part of a trend, or is it an isolated deviation? A single elevated reading against a backdrop of consistently normal readings is a different clinical situation than the third consecutive increase.

Participant symptoms. Does the participant report any symptoms that could be associated with this finding? A heart rate of 112 bpm in a participant who feels fine is a different picture than 112 bpm in a participant who reports palpitations and lightheadedness.

Relevant medical history and concomitant medications. Is the participant on an antihypertensive that they may have missed? Do they have a baseline condition that explains the reading? Has a relevant concomitant medication been started, stopped, or adjusted?

Repeat measurement results. If you obtained a repeat vital sign per protocol, what was the result? Did the abnormality persist, resolve, or worsen?

This is not busywork. This is the clinical picture that allows the investigator to make an informed determination. When a coordinator presents a complete picture, the investigator can make a confident, well-supported decision in minutes. When the coordinator presents a bare number, the investigator must ask a series of follow-up questions that consume time and -- I have seen this more often than I would like -- sometimes get deferred to "later" because the clinic is busy. And "later" becomes "forgotten."

Physical examination findings as adverse events

Physical examination findings follow the same clinical significance pathway as vital signs, but they introduce a complication: they require clinical observation skills that go beyond numerical comparison. A vital sign either exceeds a threshold or it does not. A physical examination finding -- a new rash, an enlarged lymph node, a new heart murmur, an abnormal neurological reflex -- requires the examiner to notice it, characterize it, and compare it against what was documented at baseline.

The baseline physical examination, completed during screening or the first study visit, establishes the reference point. Any new finding that was not present at baseline, or any worsening of a finding that was documented at baseline, is a potential adverse event that requires clinical significance assessment.

Consider a few examples:

A participant's screening exam documented mild bilateral lower extremity edema, grade 1. At Week 8, the investigator notes the edema has progressed to moderate, pitting, extending to the mid-shin. This is a worsening of a baseline finding -- a potential AE.

A participant's screening exam showed clear skin. At Week 4, the investigator identifies a new maculopapular rash across the trunk. This is a new finding not present at baseline -- a potential AE.

A participant's screening exam documented a grade 2/6 systolic murmur. At Week 12, the exam is unchanged. This is a stable baseline finding -- not an AE.

The pattern is the same every time: compare to baseline, identify what is new or changed, bring new or worsening findings to the investigator for clinical significance assessment.

Protocol-specific approaches: why you must know your protocol

I have made this point several times in this lesson, and I make it again here with emphasis, because it is not a theoretical nicety -- it is a practical necessity that determines whether you identify adverse events correctly.

Different protocols handle objective findings differently. The variation is not subtle. Consider how three real protocol approaches might differ for the same clinical scenario -- a participant whose weight has increased by 4 kg since baseline:

Protocol A defines weight gain of greater than 5% from baseline as requiring AE evaluation. A participant who weighs 80 kg at baseline and gains 4 kg (5%) meets the threshold exactly. The coordinator flags it for investigator assessment.

Protocol B does not include specific weight change thresholds. Weight is measured at every visit per the schedule of assessments, but AE determination is left to investigator judgment. The coordinator notes the trend and asks the investigator whether the change warrants AE documentation.

Protocol C defines weight gain as an adverse event only when it is accompanied by clinical signs of fluid retention (edema, pulmonary congestion). The 4 kg gain alone does not trigger AE evaluation unless those clinical signs are present.

Same participant. Same weight change. Three different protocol-driven outcomes. And the coordinator who has not reviewed the protocol's AE reporting criteria cannot navigate any of them correctly.

Bringing it together: the coordinator's systematic approach

Let me synthesize the pathway into what it looks like in practice -- not as an abstract framework but as the sequence of actions a coordinator performs at every study visit where vital signs and physical examinations are collected.

Before the visit, you have your protocol's vital sign thresholds accessible at the station. You have reviewed the participant's prior values so you know their personal baseline and recent trend.

During the visit, you obtain vital signs per protocol specifications. You compare each value against the protocol-defined thresholds. For any value that meets or exceeds a threshold, you obtain a repeat measurement if the protocol requires it. If the abnormality persists, you prepare the clinical picture -- current value, prior values, repeat result, participant symptoms, relevant medical history, concomitant medications -- and present it to the investigator.

During the physical examination, you ensure that the investigator or sub-investigator compares findings against the baseline exam. For any new finding or any worsening of a baseline finding, you confirm whether the finding warrants AE documentation. You record the investigator's clinical significance determination in the source record.

After the visit, you verify that every AE determination -- whether affirmative or negative -- is documented. The vital sign value is in the source record and the CRF. If it was determined to be an AE, the AE documentation captures onset, description, and severity per Module 4 standards (which you will learn later in this course). If it was not determined to be an AE, the investigator's rationale is nonetheless recorded.

This is systematic. It is repeatable. And it ensures that no objective finding slips through the cracks because the participant "felt fine."

A blood pressure reading and a question

A participant sits in the clinic chair, cuff deflating. The reading appears: 158/96 mmHg. At the prior visit, two weeks ago, it was 132/84. The participant feels fine -- no headache, no blurred vision, no chest discomfort. Just a number on a screen.

Is this an adverse event?

The honest answer -- the answer that separates competent coordinators from truly skilled ones -- is: it depends. And what it depends on is the subject of this entire lesson. It depends on what the protocol defines as a reportable vital sign threshold. It depends on whether the investigator considers this change clinically significant. It depends on context that no automated system can evaluate -- did the participant rush into the clinic from the parking garage? Did they forget their antihypertensive medication this morning? Have prior readings shown an upward trend, or is this an isolated spike?

In the previous lesson, you learned how to elicit adverse events through what participants tell you -- their subjective reports. This lesson shifts to what the data tells you. Vital sign measurements, physical examination findings, and clinical observations are objective indicators that can reveal adverse events the participant does not feel, does not notice, or does not think to mention. But unlike a participant who says "I have been having terrible headaches," an elevated blood pressure reading does not announce itself as an adverse event. It requires interpretation. And interpretation requires a framework.

From measurement to determination: the vital sign pathway

Every vital sign collected during a study visit follows a decision pathway, whether the coordinator recognizes it or not. Making that pathway explicit -- and following it deliberately -- is what ensures consistent, defensible AE identification.

The pathway has four steps:

Step 1 -- Value obtained. The coordinator measures the vital sign according to the protocol's specifications: correct technique, correct timing, correct conditions. (This course assumes you know how to measure vital signs accurately. What we teach here is what to do with the number once you have it.)

Step 2 -- Compare against protocol thresholds. The coordinator checks the value against whatever thresholds the protocol defines. Does this reading exceed an absolute threshold? Does the change from baseline exceed a protocol-defined limit? This is a factual comparison, not a judgment call.

Step 3 -- Investigator assesses clinical significance. If the value meets or exceeds a threshold, or if the coordinator identifies a change that warrants medical review, the investigator evaluates whether the finding is clinically significant. This is the step where medical judgment enters the process.

Step 4 -- Determination. If the investigator determines the finding is clinically significant, it is documented as an adverse event. If not, the value is still recorded in the source documents -- it is part of the clinical record -- but no AE entry is generated.

This is the pathway for all objective findings. It applies to blood pressure, heart rate, temperature, respiratory rate, oxygen saturation, weight, and physical examination observations. The specifics change with each vital sign, but the decision architecture remains the same.

Protocol thresholds: absolute versus change-from-baseline

Not all protocols define vital sign thresholds the same way. I have reviewed protocols from dozens of sponsors, and the variation is considerable. Understanding which approach your protocol uses is not optional preparation -- it is essential knowledge that must be mastered before the first participant visit.

Absolute thresholds define a fixed value that triggers assessment. For example: "A systolic blood pressure greater than 180 mmHg or less than 90 mmHg requires AE evaluation." The advantage of absolute thresholds is simplicity -- anyone can compare a measured value against a fixed number. The limitation is that they ignore the participant's starting point. A participant whose baseline systolic pressure is 170 mmHg is a different clinical situation than a participant whose baseline is 110 mmHg, even when both read 185 mmHg at a study visit.

Change-from-baseline thresholds define a reportable change relative to the participant's own baseline. For example: "A heart rate increase of greater than 25% from baseline requires AE evaluation." These thresholds are more sensitive to individual variation -- they detect meaningful change even when the absolute value remains within normal limits. A heart rate increase from 72 bpm to 92 bpm does not breach any absolute threshold, but it represents a 28% increase that would trigger assessment under a 25% change-from-baseline rule.

Combined approaches use both. A protocol might require AE evaluation for "systolic blood pressure greater than 180 mmHg OR an increase greater than 30 mmHg from baseline." This captures both the participant who reaches a dangerous absolute level and the participant who experiences a large shift from their personal normal.

The examples in the table above are illustrative -- your protocol may use entirely different values, and some protocols leave vital sign AE thresholds to investigator discretion without specifying numerical cutoffs at all. The point is not to memorize these numbers. The point is to know where your protocol defines its thresholds, what type of threshold it uses, and how to apply it at every visit.

A practical recommendation: before the first participant visit on any study, create a reference card -- a single page that lists every vital sign threshold the protocol defines, the type of threshold (absolute, change-from-baseline, or combined), and the required action when a threshold is breached. Keep this card at the vital signs station. When a reading appears abnormal, you should not need to flip through a 300-page protocol to determine whether it exceeds the threshold. That information should be immediately accessible.

Clinical significance: the gateway concept

This is, in my view, the most important concept in this lesson -- and one of the most important in the entire course. If you understand clinical significance and how it operates as a gateway between abnormal findings and adverse events, you will navigate the gray areas of objective AE identification with confidence. If you do not, you will either over-report (flagging every out-of-range value as an AE) or under-report (dismissing meaningful changes because the participant "feels fine").

Here is the principle, stated plainly:

An abnormal value is not automatically an adverse event. It becomes an adverse event when the investigator determines it is clinically significant.

This applies to vital signs, laboratory values (which the next lesson covers in detail), and physical examination findings. The normal range for a given parameter is a statistical construct -- it defines the central 95% of values in a healthy reference population. By definition, 5% of healthy individuals fall outside the normal range at any given time without any pathology. A blood pressure of 142/88 mmHg may be outside the textbook normal range, but if the participant has a documented history of controlled hypertension and this reading is consistent with their usual values, it is not a clinically significant finding in the context of this study.

Presenting data to support investigator judgment

The investigator's clinical significance determination is only as good as the information the coordinator puts in front of them. Telling the investigator "the blood pressure was high" is not the same as presenting a complete clinical picture. And the difference matters -- not in theory, but at the moment when the investigator must decide whether to document a finding as an adverse event.

When bringing a vital sign concern to the investigator, the coordinator should present:

The current value and the context. Not just "158/96" but "158/96, measured after five minutes of seated rest per protocol specifications."

Prior values. What were the participant's readings at baseline and at previous visits? Is this value part of a trend, or is it an isolated deviation? A single elevated reading against a backdrop of consistently normal readings is a different clinical situation than the third consecutive increase.

Participant symptoms. Does the participant report any symptoms that could be associated with this finding? A heart rate of 112 bpm in a participant who feels fine is a different picture than 112 bpm in a participant who reports palpitations and lightheadedness.

Relevant medical history and concomitant medications. Is the participant on an antihypertensive that they may have missed? Do they have a baseline condition that explains the reading? Has a relevant concomitant medication been started, stopped, or adjusted?

Repeat measurement results. If you obtained a repeat vital sign per protocol, what was the result? Did the abnormality persist, resolve, or worsen?

This is not busywork. This is the clinical picture that allows the investigator to make an informed determination. When a coordinator presents a complete picture, the investigator can make a confident, well-supported decision in minutes. When the coordinator presents a bare number, the investigator must ask a series of follow-up questions that consume time and -- I have seen this more often than I would like -- sometimes get deferred to "later" because the clinic is busy. And "later" becomes "forgotten."

Physical examination findings as adverse events

Physical examination findings follow the same clinical significance pathway as vital signs, but they introduce a complication: they require clinical observation skills that go beyond numerical comparison. A vital sign either exceeds a threshold or it does not. A physical examination finding -- a new rash, an enlarged lymph node, a new heart murmur, an abnormal neurological reflex -- requires the examiner to notice it, characterize it, and compare it against what was documented at baseline.

The baseline physical examination, completed during screening or the first study visit, establishes the reference point. Any new finding that was not present at baseline, or any worsening of a finding that was documented at baseline, is a potential adverse event that requires clinical significance assessment.

Consider a few examples:

A participant's screening exam documented mild bilateral lower extremity edema, grade 1. At Week 8, the investigator notes the edema has progressed to moderate, pitting, extending to the mid-shin. This is a worsening of a baseline finding -- a potential AE.

A participant's screening exam showed clear skin. At Week 4, the investigator identifies a new maculopapular rash across the trunk. This is a new finding not present at baseline -- a potential AE.

A participant's screening exam documented a grade 2/6 systolic murmur. At Week 12, the exam is unchanged. This is a stable baseline finding -- not an AE.

The pattern is the same every time: compare to baseline, identify what is new or changed, bring new or worsening findings to the investigator for clinical significance assessment.

Protocol-specific approaches: why you must know your protocol

I have made this point several times in this lesson, and I make it again here with emphasis, because it is not a theoretical nicety -- it is a practical necessity that determines whether you identify adverse events correctly.

Different protocols handle objective findings differently. The variation is not subtle. Consider how three real protocol approaches might differ for the same clinical scenario -- a participant whose weight has increased by 4 kg since baseline:

Protocol A defines weight gain of greater than 5% from baseline as requiring AE evaluation. A participant who weighs 80 kg at baseline and gains 4 kg (5%) meets the threshold exactly. The coordinator flags it for investigator assessment.

Protocol B does not include specific weight change thresholds. Weight is measured at every visit per the schedule of assessments, but AE determination is left to investigator judgment. The coordinator notes the trend and asks the investigator whether the change warrants AE documentation.

Protocol C defines weight gain as an adverse event only when it is accompanied by clinical signs of fluid retention (edema, pulmonary congestion). The 4 kg gain alone does not trigger AE evaluation unless those clinical signs are present.

Same participant. Same weight change. Three different protocol-driven outcomes. And the coordinator who has not reviewed the protocol's AE reporting criteria cannot navigate any of them correctly.

Bringing it together: the coordinator's systematic approach

Let me synthesize the pathway into what it looks like in practice -- not as an abstract framework but as the sequence of actions a coordinator performs at every study visit where vital signs and physical examinations are collected.

Before the visit, you have your protocol's vital sign thresholds accessible at the station. You have reviewed the participant's prior values so you know their personal baseline and recent trend.

During the visit, you obtain vital signs per protocol specifications. You compare each value against the protocol-defined thresholds. For any value that meets or exceeds a threshold, you obtain a repeat measurement if the protocol requires it. If the abnormality persists, you prepare the clinical picture -- current value, prior values, repeat result, participant symptoms, relevant medical history, concomitant medications -- and present it to the investigator.

During the physical examination, you ensure that the investigator or sub-investigator compares findings against the baseline exam. For any new finding or any worsening of a baseline finding, you confirm whether the finding warrants AE documentation. You record the investigator's clinical significance determination in the source record.

After the visit, you verify that every AE determination -- whether affirmative or negative -- is documented. The vital sign value is in the source record and the CRF. If it was determined to be an AE, the AE documentation captures onset, description, and severity per Module 4 standards (which you will learn later in this course). If it was not determined to be an AE, the investigator's rationale is nonetheless recorded.

This is systematic. It is repeatable. And it ensures that no objective finding slips through the cracks because the participant "felt fine."